Gary Cheung1, Janli Stapelberg. 1. Mental Health Services for Older People, Auckland District Health Board, Private Bag 92189, Greenlane Clinical Centre, Auckland, New Zealand. GCheung@adhb.govt.nz
Abstract
AIM: This meta-analysis is aimed to determine the efficacy of quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD). METHOD: Our electronic search included MEDLINE (1950-2009), Cochrane Central Register of Controlled Trials and PsychINFO. We also did a hand search of the International Psychogeriatric Association poster presentations and checked the National trial registry data bases from USA, UK, RSA, Holland, Australia and New Zealand. We included double-blinded randomised placebo-controlled trials studies that measured BPSD with the Neuropsychiatric Inventory (NPI). The Clinical Global Impression of Change scale (CGI-C) was our secondary outcome. RESULTS: Six sets of data were included in this meta-analysis. Patients receiving quetiapine improved when compared to placebo with a weighted mean difference of - 3.05 (95% CI: -6.10, -0.01) and -0.31 (95% CI: -0.54, -0.08) respectively on the NPI score and CGI-C score. CONCLUSION: This meta-analysis found that quetiapine is statistically more efficacious than placebo in the treatment of BPSD as measured by the NPI and CGI-C. However, improvement is of a small magnitude and observable clinical significance is questionable.
AIM: This meta-analysis is aimed to determine the efficacy of quetiapine for the treatment of behavioural and psychological symptoms of dementia (BPSD). METHOD: Our electronic search included MEDLINE (1950-2009), Cochrane Central Register of Controlled Trials and PsychINFO. We also did a hand search of the International Psychogeriatric Association poster presentations and checked the National trial registry data bases from USA, UK, RSA, Holland, Australia and New Zealand. We included double-blinded randomised placebo-controlled trials studies that measured BPSD with the Neuropsychiatric Inventory (NPI). The Clinical Global Impression of Change scale (CGI-C) was our secondary outcome. RESULTS: Six sets of data were included in this meta-analysis. Patients receiving quetiapine improved when compared to placebo with a weighted mean difference of - 3.05 (95% CI: -6.10, -0.01) and -0.31 (95% CI: -0.54, -0.08) respectively on the NPI score and CGI-C score. CONCLUSION: This meta-analysis found that quetiapine is statistically more efficacious than placebo in the treatment of BPSD as measured by the NPI and CGI-C. However, improvement is of a small magnitude and observable clinical significance is questionable.
Authors: Thitiporn Supasitthumrong; Blanca M Bolea-Alamanac; Selim Asmer; Vincent L Woo; Petal S Abdool; Simon J C Davies Journal: Br J Clin Pharmacol Date: 2019-02-08 Impact factor: 4.335
Authors: Andrea Iaboni; Susan E Bronskill; Katelyn B Reynolds; Xuesong Wang; Paula A Rochon; Nathan Herrmann; Alastair J Flint Journal: Drugs Aging Date: 2016-07 Impact factor: 3.923
Authors: Márcio G Soeiro-DE-Souza; Vasco Videira Dias; Giovanni Missio; Vicent Balanzá-Martinez; Leandro Valiengo; André F Carvalho; Ricardo Alberto Moreno Journal: Exp Ther Med Date: 2015-01-23 Impact factor: 2.447
Authors: Tessa A Hulshof; Sytse U Zuidema; Peter J K van Meer; Christine C Gispen-de Wied; Hendrika J Luijendijk Journal: Int J Methods Psychiatr Res Date: 2018-12-04 Impact factor: 4.035
Authors: Anna Partyka; Anna Wasik; Magdalena Jastrzębska-Więsek; Paweł Mierzejewski; Przemysław Bieńkowski; Marcin Kołaczkowski; Anna Wesołowska Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2016-03-16 Impact factor: 3.000
Authors: Simon Jc Davies; Amer M Burhan; Donna Kim; Philip Gerretsen; Ariel Graff-Guerrero; Vincent L Woo; Sanjeev Kumar; Sarah Colman; Bruce G Pollock; Benoit H Mulsant; Tarek K Rajji Journal: J Psychopharmacol Date: 2018-01-17 Impact factor: 4.153